MXPA04000068A - Conjugados de progenipoyetina modificados quimicamente. - Google Patents

Conjugados de progenipoyetina modificados quimicamente.

Info

Publication number
MXPA04000068A
MXPA04000068A MXPA04000068A MXPA04000068A MXPA04000068A MX PA04000068 A MXPA04000068 A MX PA04000068A MX PA04000068 A MXPA04000068 A MX PA04000068A MX PA04000068 A MXPA04000068 A MX PA04000068A MX PA04000068 A MXPA04000068 A MX PA04000068A
Authority
MX
Mexico
Prior art keywords
modified
chemically
progenipoietin
conjugates
present
Prior art date
Application number
MXPA04000068A
Other languages
English (en)
Inventor
R Siegel Ned
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA04000068A publication Critical patent/MXPA04000068A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion provee progenipoyetinas, ProGPs, modificadas quimicamente, preparadas uniendo un polimero soluble en agua con la proteina; la proteina modificada quimicamente de acuerdo con la presente invencion puede tener una actividad incrementadora de neutrofilos de duracion mucho mayor que la ProGP no modificada, permitiendo reducir la dosis y la oportunidad de programarla.
MXPA04000068A 2001-06-22 2002-06-14 Conjugados de progenipoyetina modificados quimicamente. MXPA04000068A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30036201P 2001-06-22 2001-06-22
PCT/US2002/018810 WO2003000179A2 (en) 2001-06-22 2002-06-14 Chemically-modified progenipoietin conjugates

Publications (1)

Publication Number Publication Date
MXPA04000068A true MXPA04000068A (es) 2005-06-06

Family

ID=23158770

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04000068A MXPA04000068A (es) 2001-06-22 2002-06-14 Conjugados de progenipoyetina modificados quimicamente.

Country Status (15)

Country Link
US (1) US20060052291A1 (es)
EP (1) EP1404354A4 (es)
JP (1) JP2005512951A (es)
KR (1) KR20040069980A (es)
CN (1) CN101426511A (es)
BR (1) BR0211192A (es)
CA (1) CA2450950A1 (es)
CZ (1) CZ20033537A3 (es)
EA (1) EA006368B1 (es)
IL (1) IL159496A0 (es)
MX (1) MXPA04000068A (es)
NO (1) NO20035742L (es)
PL (1) PL367410A1 (es)
WO (1) WO2003000179A2 (es)
ZA (1) ZA200309863B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1848458B1 (en) * 2005-02-16 2009-11-04 Micromet AG Use of activated polymers for separation of protein and polypeptide multimers
EP1861125A2 (en) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Conjugates of an hgh moiety and peg derivatives
WO2010123827A1 (en) * 2009-04-20 2010-10-28 The Regents Of The University Of California Engineered demeter 5-methylcytosine dna glycosylase with improved yield, stability and solubility
KR200483859Y1 (ko) 2015-10-28 2017-07-04 주식회사 키유틸리티 충전장치 수납 및 휴대용 기기 거치용 장치
AU2018348138A1 (en) * 2017-10-11 2020-04-23 Ambrx, Inc. Porcine G-CSF variants and their uses
EP3731871B1 (en) * 2017-12-29 2023-10-04 F. Hoffmann-La Roche AG Process for providing pegylated protein composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0702723T3 (da) * 1993-04-21 2003-01-13 Pasteur Institut Biokompatibelt implantat til ekspression og udskillelse af terapeutisk forbindelse in vivo
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
GB2294047A (en) * 1994-10-14 1996-04-17 Merck & Co Inc Synthetic peptides for use as epitopes specific for HIV
SE507527C2 (sv) * 1996-10-11 1998-06-15 Ericsson Telefon Ab L M Flerbandsmottagare som genererar en mellanfrekvens som är gemensam för de olika frekvensbanden, och förfarande för densamma
US6251665B1 (en) * 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom

Also Published As

Publication number Publication date
CZ20033537A3 (cs) 2004-08-18
US20060052291A1 (en) 2006-03-09
EA006368B1 (ru) 2005-12-29
PL367410A1 (en) 2005-02-21
NO20035742L (no) 2004-02-23
ZA200309863B (es) 2006-06-28
EA200400070A1 (ru) 2004-06-24
CN101426511A (zh) 2009-05-06
JP2005512951A (ja) 2005-05-12
EP1404354A4 (en) 2005-04-20
NO20035742D0 (no) 2003-12-19
KR20040069980A (ko) 2004-08-06
BR0211192A (pt) 2004-10-26
WO2003000179A3 (en) 2003-12-11
CA2450950A1 (en) 2003-01-03
WO2003000179A2 (en) 2003-01-03
IL159496A0 (en) 2004-06-01
EP1404354A2 (en) 2004-04-07

Similar Documents

Publication Publication Date Title
MXPA04004809A (es) Conjugados de hormona de crecimiento humana modificada quimicamente.
MXPA05004993A (es) Conjugados de hormona del crecimiento humana modificados quimicamente.
DE59905247D1 (de) Wässrige reaktive spachtelmassen (ii)
RS20060320A (en) Substituted indazole-o-glucosides
SG130189A1 (en) Substituted indole-o-glucosides
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
UA86042C2 (en) Substituted indazole-o-glucosides
WO2002039998A3 (en) Methods and compositions for regulating memory consolidation
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
WO2001076640A3 (en) Chemically modified novel erythropoietin stimulating protein compositions and methods
TW200738270A (en) Method of treating depression using a TNFα antibody
TW200718237A (en) Link assignment messages in lieu of assignment acknowledgement messages
EA200900643A1 (ru) Пептиды, содержащие триптофан
YU101503A (en) A novel engineered superantigen for human therapy
MX2008002492A (es) Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
TW200724159A (en) Stable emulsion composition
TW200621160A (en) Anti-termite agent
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
MY122877A (en) Composition.
MXPA04000068A (es) Conjugados de progenipoyetina modificados quimicamente.
WO2001076639A3 (en) Chemically-modified myelopoietin conjugates
GB0004827D0 (en) Compositions
MXPA04002103A (es) Una proteina de union a caspasa-8, su preparacion y uso.
DE60225560D1 (de) Zusammensetzung enthaltend epigallocatechin-gallat
HK1082510A1 (en) Promoter to il-18bp, its preparation and use